1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
These two stocks could have vastly different long-term performances.
Mindfully Curated
These two stocks could have vastly different long-term performances.
It’s already zooming higher in the second half after a highly anticipated fee raise.
Revenue growth could be surprisingly good. But what about profits?
For a start-up EV maker like Rivian, it’s huge that its debut model keeps winning plaudits from critics and consumers alike.
A number of catalysts could propel the industrial conglomerate’s stock higher in 2024.
The energy-efficient Bitcoin miner could have a bright future.
If you are looking for stocks that have fallen out of favor on Wall Street, then consider Stanley Black & Decker and Nucor today.
The company’s recent earnings results weren’t impressive, and they led to a steep sell-off.
These two funds are an income investor’s best friend.
Alphabet has been a strong performer so far in 2024, but it could lead in the second half.
Tesla’s stock price is on fire due to better-than-expected delivery numbers.
Tesla reports second-quarter earnings on that date.
There’s no denying that this is one of the most innovative businesses of the past decade.
The global renewable-energy giant continues to make needle-moving deals.
Nu is a surprising Buffett stock.
Could this EV battery technology company be a big winner for patient investors?
Stocks with big run-ups behind them can still be smart buys.
Both of these stocks trade in the triple digits, which might be enough to motivate their management teams to do stock splits.
Over the past 10 years, these stocks have averaged second-half returns of more than 28%.
Opportunities in the artificial intelligence (AI) space are expanding beyond popular stocks like Nvidia.